Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 19/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 11/20 | 1.00 |
| ▸ | TUBB | P07437 | 11/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 11/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 11/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 11/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 11/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 11/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 11/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 11/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 11/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 11/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 11/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 11/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 11/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31032788 | 0.89 | TUBB1 (0.80) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14427612 | 0.89 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6129276 | 0.86 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6129277 | 0.86 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6129111 | 0.85 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6346609 | 0.85 | TUBB1 (0.74) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL6345988 | 0.84 | TUBB1 (0.73) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL6352937 | 0.84 | TUBB1 (0.73) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL28984318 | 0.84 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6776580 | 0.83 | TUBB1 (0.73) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-8552066-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552066-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-09-02 | — | — | US | disclosed |
| US-7714025-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-7598294-B2 | Antiproliferative agents; antiinflammatory agents; anticancer agents; diagnosis, therapy | SPEAR THERAPEUTICS LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | LAWRENCE NICHOLAS JAMES (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | AURKA, AURKB, HDAC4 | TUBB1 567/4885TUBB4A 61/4885TUBB 472/4885 |
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | TUBA1C, SARS1, TUBB1 | TUBB1 3/4885TUBB4A 18/4885TUBB 4/4885 |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | TUBB1 2/4885TUBB4A 7/4885TUBB 5/4885 |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | TUBA1C, SARS1, TUBB1 | TUBB1 3/4885TUBB4A 18/4885TUBB 4/4885 |
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | RB1, BCL3, CCNO | TUBB1 3172/4885TUBB4A 2184/4885TUBB 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.